id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-351457-fzj3ciif	Vezzoli, Pamela	Cutaneous lupus erythematosus patients in a high‐epidemic COVID‐19 area, Bergamo, Italy	2020-06-07		.txt	text/plain	579	42	49	Dear editor, the current pandemic of coronavirus disease 2019 (COVID-19) has raised the interest in reporting the management's experience with systemic lupus erythematosus (SLE) patients under long-term treatment with immunosuppressor drugs or hydroxychloroquine (HCQ). 5, 6 However, no data about the management of risk infection in cutaneous lupus erythematosus (CLE) during the current pandemic are present in the literature to date. Our hospital is located in a high-epidemic area of Lombardy: we decided to advice patients affected by SLE with cutaneous manifestations and CLE, to scrupulously comply with hygiene rules and protective devices use, to maintain social distancing, not to spontaneously suspend ongoing therapy and to inform the dermatologist in case of the onset of symptoms, as suggested This article is protected by copyright. Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19 Coronavirus Disease-2019: Implication for the care and management of patients with systemic lupus erythematosus	./cache/cord-351457-fzj3ciif.txt	./txt/cord-351457-fzj3ciif.txt